Table 3.

All treatment-related adverse events(TRAEs) in the SAS.

TRAEs	No.(%) of patient
	TCCA(n = 30)		TCC(n = 30)
	Any grade	≥G3	Any grade	≥G3
ALL TRAEs	30(100)	12(40.0)	30(100)	8(26.7)
Leukopenia	14(46.7)	4(13.3)	7(23.3)	2(6.7)
Neutropenia	12(40)	5(16.7)	8(26.7)	1(3.3)
Lymphopenia	6(20)	2(6.7)	4(13.3)	1(3.3)
Thrombocytopenia	7(23.3)	3(10)	7(23.3)	3(10)
Rash	7(23.3)	1(3.3)	3(10)	1(3.3)
Nausea/Vomiting	18(60)	0(0)	20(66.7)	2(6.7)
Fatigue	22(73.3)	0(0)	22(73.3)	0(0)
Anemia	11(36.7)	0(0)	17(56.7)	0(0)
Anorexia/Dysgeusia	25(83.3)	1(3.3)	24(80)	1(3.3)
Diarrhea	1(3.3)	0(0)	2(6.7)	0(0)
Numbness/ Hypoesthesia	14(46.7)	0(0)	10(33.3)	0(0)
Alopecia	30(100)	0(0)	30(100)	0(0)
Constipation	13(43.3)	0(0)	17(56.7)	0(0)
Proteinuria	2(6.7)	1(3.3)	0(0)	0(0)
Interstitial pneumonia	2(6.7)	0(0)	1(3.3)	0(0)
T3 reduction	6(20)	0(0)	1(3.3)	0(0)
T3 elevation	4(13.3)	0(0)	6(20)	0(0)
T4 reduction	3(10)	0(0)	0(0)	0(0)
T4 elevation	5(16.7)	0(0)	2(6.7)	0(0)
Myocarditis	5(16.7)	0(0)	6(20)	0(0)
Hypertension	2(6.7)	2(6.7)	0(0)	0(0)
RCCEP	6(20)	0(0)	20(66.7)	1(3.3)
Hypoproteinemia	9(30)	0(0)	5(16.7)	0(0)
AST/ALT Elevation	3(10)	0(0)	3(10)	0(0)
Low sodium/Low potassium	3(10)	0(0)	1(3.3)	0(0)
Myalgia	18(60)	0(0)	22(73.3)	0(0)
Epistaxis	1(3.3)	0(0)	0(0)	0(0)
Venous thrombosis	0(0)	0(0)	1(3.3)	1(3.3)

Data are n (%).RCCEP, reactive cutaneous-capillary endothelial proliferation.